Johnson & Johnson Completes Acquisition of Halda Therapeutics to Expand Cancer Treatment Platform
Johnson & Johnson announced the completed acquisition of Halda Therapeutics OpCo, Inc. for approximately $3.05 billion in cash, bringing Halda’s proprietary RIPTAC™ platform and oncology pipeline into its Innovative Medicine portfolio. The deal adds HLD-0915, an oral clinical-stage therapy for prostate cancer, and several earlier solid tumor candidates, enhancing J&J’s targeted cancer treatment capabilities. Johnson & Johnson leaders emphasized that this strategic milestone supports their commitment to breakthrough science and transformative oncology medicines. The acquisition will be accounted for as a business combination, with expected effects on adjusted earnings per share in 2025 and 2026. 
Johnson & Johnson Completes Acquisition of Halda Therapeutics to Expand Cancer Treatment Platform